drugset / Trial / NCT02829827

A Phase 2 Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)

NCT02829827

Phase 2 Terminated 3 enrolled UCB Biopharma S.P.R.L.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and tolerability, the pharmacokinetics and the efficacy of radiprodil in abolishing clinical spasms in subjects with drug-resistant infantile spasms

Timeline

Start
2017-12-04
Primary completion
2018-10-02
Completion
2018-10-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Radiprodil Small molecule

Indications